Horizon Therapeutics is a drug developer for rare diseases, specializing in the development and production of biosimilar drugs, and is committed to helping patients solve rare diseases and rheumatic diseases. Amgen is closing in on its acquisition of star biotech company Horizon Therapeutics in a deal valued at up to $20 billion, which would be the biggest pharmaceutical M&A this year.
This article is transferred from: https://www.itjuzi.com/merger/9538
This site is only for collection, and the copyright belongs to the original author.